UPM Biomedicals and CELLINK form collaboration for groundbreaking 3D bioprinting developments

UPM Biomedicals is excited to announce its collaboration with bioconvergence company CELLINK. The partnership brings together UPM’s expertise for producing non-animal derived, nanocellulose biomaterials with CELLINK’s years of experience in method development for 3D bioprinting, offering new groundbreaking solutions to this growing life sciences market.

Advances in 3D printing in the past decade have been outstanding, and the technology is becoming more widely used for various cutting-edge applications. 3D bioprinting is already important in areas such as cancer research, where tumour models can be printed to test their response to different treatments. More recently scientists have been exploring the use of this technology in a clinical setting, with the possibility of printing tissues or organs that can then be transplanted into patients. Using non-animal derived raw materials, such as UPM’s nanofibrillar cellulose, for bio-ink formulations makes transplants into humans much more effective, reducing the possibility of an immune response or rejection.

The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.

“Our material is made from just nanocellulose and water, with no animal-derived components and no contaminants. We were the first ones to produce it in accordance with the standard ISO 13485 quality management of medical devices, which is a critical first step for future clinical applications. Together with our high-quality materials and CELLINK’s 3D printing capabilities, we will produce the future of regenerative medicine one drop at a time”, says Johana Kuncova-Kallio, Director of UPM Biomedicals.

“We were the first company to bring cellulose bio-ink to the market and partnering with UPM has opened up a world of possibilities. Companies need to work together to make an impact, and this collaboration is doing exactly that. We definitely see these technologies being used for tissue repair or replacement in the future, and that’s very exciting”, adds Erik Gatenholm, CEO of CELLINK.
https://www.upm.com/about-us/for-media/releases/2021/03/upm-biomedicals-and-cellink-form-collaboration-for-groundbreaking-3d-bioprinting-developments/

Related Posts

International Paper Company Announces Completion of Sylvamo Corporation Spin-Off

International Paper Company announced the completion of its previously announced separation and spin-off of its global printing papers business, now operating as Sylvamo Corporation (NYSE: SLVM). Each International Paper shareholder received one share of Sylvamo common stock for every eleven shares of International Paper common stock held on the record date. International Paper continues to own approximately 19.9% of the outstanding shares of Sylvamo common stock. "The spin-off enhances the strategic flexibility and focus for long-term success and value creation at both companies. International Paper is now a highly-advantaged, corrugated packaging-focused company, well-positioned to grow earnings and cash generation," said Mark Sutton, Chairman and Chief Executive Officer. Sylvamo common stock is expected to begin "regular way" trading on the New York Stock Exchange today under the symbol "SLVM" and the CUSIP number 871332 102. The receipt of Sylvamo common stock in the distribution is tax-free to International Paper stockholders for U.S. federal income tax purposes, except for the gain or loss attributable to cash received in lieu of fractional shares of Sylvamo common stock. International Paper shareholders are urged to consult with their tax advisors with respect to the U.S. federal, state and local or foreign tax consequences, as applicable, of the spin-off.

Stora Enso divests non-core forest holdings in southern Sweden

As part of its forest land optimisation, Stora Enso has signed an agreement to divest forest assets located in southern Sweden to the forestry fund Silvestica Green Forest AB. The total area of forest land in the transaction is approximately 5 200 hectares. The selling price is approximately SEK 940 million (EUR 90 million). The transaction is in line with Stora Enso’s policy of divesting non-core assets. The forest areas are located geographically far away from Stora Enso’s other forest lands, which limits the scale benefits. The forest land divestment has no impact on Stora Enso’s nearby Hylte Mill, which uses other wood supply sources for its production. The forest land corresponds to less than 0.5% of Stora Enso’s total forest land area in Sweden.

Restarting PM5 at Norske Skog Saugbrugs

Following the rockslide and subsequent production stop at Saugbrugs PM6 (paper machine 6) in April this year, Norske Skog has decided to restart production at the previously idled PM5. The restart of PM5 allows Norske Skog to continue supplying SC magazine paper to its customers and keep its market position. “The decision to restart production at PM5 is important to maintain Saugbrugs as a preferred supplier of SC paper in Europe, while the restoration work is ongoing at the PM6 plant,” says Per Ivar Berg, Managing Director at Norske Skog Saugbrugs. The business interruption at PM6 is covered by insurance. Cash flows relating to the restart and production from PM5 will be netted against the insurance coverage, thus the financial impact for Norske Skog Saugbrugs will be largely neutral. Prior to being idled in late 2020, PM5 had a production capacity of up to 100 000 tonnes of SC magazine paper. Saugbrugs PM6 has a capacity of 260 000 tonnes SC magazine paper. Operations at Saugbrugs PM4 continue with its capacity of 100 000 tonnes of SC paper.
Back To Top
×Close search
Search